Indaptus Therapeutics, Inc.
No SEC Form 4 filings for $INDP in the last 30 days.
See all $INDP insider activity →NewGen IVF (NIVF) rose 25% after a $1.25M share offering. SeaStar Medical (ICU) gained 23% on regulatory updates. Atara Biotherapeutics (ATRA) climbed 11% with a BLA resubmission. Indaptus Therapeutics (INDP) increased 9% without specific news. All stocks traded higher on Friday.
Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed in the Current Report on Form 8-K filed by Indaptus Therapeutics, Inc. (the “ Company ”) with the Securities and Exchange Commission on September 9, 2026 (the “ Prior Form 8-K ”), on September 8, 2026,
PDS Biotech (PDSB) announced a $22.55M PIPE financing for late-stage cancer drug development, shares up 50.64%. Avaí Bio (AVAI) completed cell bank testing, shares up 14.29%. Clene (CLNN) priced a $4M offering, shares up 25.25%. NurExone (NRX.V) partnered with NanoPass, shares up 8.06%. Cardiff Oncology (CRDF) settled a licensing dispute, shares up 4.58%. Indaptus (INDP) shares surged 16.88% without specific news.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning INDP (Indaptus Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent INDP coverage spans corporate actions, market movers and financial news.
Balance‑sheet strengthening and exploration of alternatives may support the stock.
The extension delays funding and may increase dilution risk, likely weighing on the stock.
Price move appears speculative; no fresh catalyst disclosed.
Capital raise and strategic review may improve liquidity and open M&A possibilities.
The capital raise provides near‑term funding but dilutes existing shareholders.
AlphAI scores every news story that mentions INDP with an AI model for sentiment and relevance, and aggregates insider trades from Indaptus Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
NewGen IVF (NIVF) rose 25% after a $1.25M share offering. SeaStar Medical (ICU) gained 23% on regulatory updates. Atara Biotherapeutics (ATRA) climbed 11% with a BLA resubmission. Indaptus Therapeutics (INDP) increased 9% without specific news. All stocks traded higher on Friday.
2 min readIndaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed in the Current Report on Form 8-K filed by Indaptus Therapeutics, Inc. (the “ Company ”) with the Securities and Exchange Commission on September 9, 2026 (the “ Prior Form 8-K ”), on September 8, 2026,
1 min readPDS Biotech (PDSB) announced a $22.55M PIPE financing for late-stage cancer drug development, shares up 50.64%. Avaí Bio (AVAI) completed cell bank testing, shares up 14.29%. Clene (CLNN) priced a $4M offering, shares up 25.25%. NurExone (NRX.V) partnered with NanoPass, shares up 8.06%. Cardiff Oncology (CRDF) settled a licensing dispute, shares up 4.58%. Indaptus (INDP) shares surged 16.88% without specific news.
3 min readTenon Medical (TNON) repaid $5.16M in notes, strengthening its balance sheet. AEON Biopharma (AEON) reported positive study results for ABP-450. Silexion (SLXN) announced September conference participations. Orchestra BioMed (OBIO) and Indaptus (INDP) also shared updates, with shares rising.
3 min readIndaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 8, 2026, Indaptus Therapeutics, Inc. (the “ Company ”) entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) with the purchasers party thereto (collectively, the “ Purchasers ”), pursuant to which
1 min readIndaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 2, 2026, Tim Ruan notified the Board of Directors (the “ Board ”) of Indaptus Therapeutics, Inc. (the “ Compa
1 min readIndaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 28, 2026, Indaptus Therapeutics, Inc. (the “ Company ”) entered into an Amended and Restated At the Market Offering Agreement (the “ Sales Agreement ”) with H.C. Wainwright & Co., LLC (“ Wainwright ”), which amends
2 min readIndaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK (August 13, 2026) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to immunotherapy research, today
4 min readIndaptus Therapeutics (Nasdaq: INDP) reported Q2 2026 results and a corporate update. It raised about $12.0 million via a June 17 private placement at $0.60 per share. The company discontinued further Decoy20 enrollment and has no active clinical programs. Q2 R&D fell to ~$0.4M and net loss to ~$1.8M. Cash and short-term investments were ~$11.6M at June 30.
4 min readIndaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR REGISTERED OR QUALIFIED UNDER THE SECURITIES LAWS OF ANY STATE OR FOREIGN JURISDICTION OR APPROVED OR DISAPPROV
4 min read